drugset / Trial / NCT00255047
Safety and Immune Response of Different Pediatric Combination Vaccines.
RandomizedParallel-groupOpen-labelPrevention
Summary
The overall aim of the study is to corroborate that a schedule consisting of 3 doses of Pentacel™ and a 4th dose of DAPTACEL® and ActHIB® or 4 doses of Pentacel™ or 4 doses of Quadracel and ActHIB® is as safe and immunogenic as a standard of care schedule based on 3 doses of the licensed-equivalent vaccines DAPTACEL®, Vero cell derived Inactivated Poliovirus vaccine (IPOL®), and ActHIB® and a 4th dose of DAPTACEL® and ActHIB®.
Timeline
- Start
- 2005-11
- Primary completion
- 2008-07
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ActHIB | Vaccine | 0.5 ml | Intramuscular |
| Subject | Adacel | Vaccine | 0.5 ml | Intramuscular |
| Subject | DTaP-IPV | Vaccine | 0.5 ml | Intramuscular |
| Subject | IPOL® | Unknown | 0.5 ml | Intramuscular |
| Subject | Pentacel | Vaccine | 0.5 ml | Intramuscular |